EuroAPI, the Sanofi-spunoff standalone active pharmaceutical ingredient manufacturing business, has suspended its two-week-old 2024 financial guidance after quality control deficiencies due to “potential local misconduct” led it to halt production and sale of all APIs made at the firm’s subsidiary in Italy.
Deficiencies at the firm’s site in Brindisi, 40km north of Lecce, including integrity deficiencies in documentation and quality data related to API quality control, would be
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?